Sign In
Buy MNMD
$20.69
+0 (+0%)
At Close: Jun 18, 2026
MindMed announces positive results in trial of LSD as a treatment for generalized anxiety disorder
07:39am, Thursday, 14'th Dec 2023
Mind Medicine Inc. MNMD, +3.53% said Thursday a Phase 2 trial testing LSD as a treatment for generalized anxiety disorder met its main goal, showing a statistically significant improvement in scores b
Mind Medicine (MindMed) Inc. (MNMD) Q3 2023 Earnings Call Transcript
08:39pm, Thursday, 02'nd Nov 2023
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Rob Barrow - Chief Executive Officer Schond Greenway - Chief Financial Offi
Mind Medicine: Q4 Of 2023 Data For GAD Makes This Worth A Look
06:37pm, Friday, 13'th Oct 2023
Results from the phase 2b study, using MM-120 for the treatment of patients with generalized anxiety disorder, expected Q4 of 2023. The Generalized Anxiety Disorder market is set to reach $7.4 billion
3 Pharma Stocks to Dump Before the Damage Is Done
08:00am, Sunday, 08'th Oct 2023
Pharma stocks and the biotech sector can offer explosive gains. It also offers incredibly crushing defeats in which share prices decline precipitously.
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data for MM-402 in a model for autism spectrum disorder.
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update
08:30am, Monday, 31'st Jul 2023
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will provide a corporate update and review the Company's results for the quarter ended June 30, 2023.
The 3 Best Psychedelic Stocks to Buy Now
08:00am, Thursday, 29'th Jun 2023
Psychedelic stocks have a bright future with 13.5% compound annual growth expected through 2029. That growth will certainly draw in investment funding that seeks to capitalize on growth, as psychedeli
Psychedelic clinical trials: A glimpse at hotly-anticipated upcoming results
04:01pm, Tuesday, 27'th Jun 2023
As part of the renewed interest in the potential health applications of psychedelics in recent years, companies ranging from biotechnology startups to pharmaceutical giants are conducting ground-brea
TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.
08:45am, Wednesday, 21'st Jun 2023
Blake Mycoskie, founder of the canvas-footwear phenomenon TOMS Shoes, has committed to giving $100 million to support psychedelic research and access, Mycoskie told MarketWatch in an exclusive intervi
Numinus Wellness designated as a top research site for MindMed study
08:08am, Monday, 05'th Jun 2023
Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) said it has been designated as a top research site for MindMed Inc's (NASDAQ:MNMD, NEO:MMED) Phase 2b study on MM-120 (lysergide D-tartrate) for General
MindMed to Participate at Upcoming Investor Conferences
07:00am, Thursday, 01'st Jun 2023
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed announced today that members of the Company's management team will participate in several June investor conferences.
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data of MM-402, the Company's proprietary form of R-MDMA, in a model for autism spectrum disorder.
MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study
01:48pm, Thursday, 18'th May 2023
MindMed's (MNMD) mid-stage study, evaluating MM-120 for treating general anxiety disorder, reaches over 50% enrollment mark. Its top-line data is expected in late 2023.
MindMed a ‘Speculative Buy' ahead of key trial data readouts, broker says
11:13am, Tuesday, 09'th May 2023
Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Speculative Buy' rating for MindMed (NASDAQ:MNMD, NEO:MMED) after the clinical-stage biotechnology company reaffirmed its budget
3 High-Growth Penny Stocks to Consider Buying in April 2023
06:25am, Monday, 01'st May 2023
The search for top penny stocks to buy in April, or in any month, is certainly an intriguing one. There are thousands of small and micro-cap stocks to choose from.
